Analysts Set LeMaitre Vascular, Inc. (NASDAQ:LMAT) PT at $98.00

Key Points

• LeMaitre Vascular has received a consensus rating of “Moderate Buy” from six brokerages, with an average 12-month price target of $98.00.
• Insider transactions included significant sales by directors, with John A. Roush and David B. Roberts selling a combined total of 17,376 shares, reflecting a notable decrease in their ownership stakes.
• The company reported $0.60 earnings per share for the last quarter, exceeding estimates and showing a 15.0% increase in year-over-year revenue.

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) have been assigned a consensus rating of "Hold" from the five research firms that are presently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $97.60.

Several research firms have commented on LMAT. Barrington Research raised shares of LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price objective for the company in a report on Wednesday, August 6th. Cantor Fitzgerald increased their price objective on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th.

LeMaitre Vascular Price Performance

LeMaitre Vascular stock traded up $1.38 during mid-day trading on Friday, hitting $96.71. The stock had a trading volume of 337,897 shares, compared to its average volume of 173,012. The firm has a market capitalization of $2.19 billion, a P/E ratio of 46.95, a P/E/G ratio of 2.45 and a beta of 0.79. The company has a current ratio of 13.96, a quick ratio of 11.74 and a debt-to-equity ratio of 0.46. The firm's 50 day moving average is $85.30 and its 200 day moving average is $86.46. LeMaitre Vascular has a one year low of $71.42 and a one year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.03. The company had revenue of $63.15 million during the quarter, compared to the consensus estimate of $62.48 million. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. LeMaitre Vascular's quarterly revenue was up 15.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.52 EPS. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. On average, sell-side analysts forecast that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 4th. Shareholders of record on Thursday, August 21st will be issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend is Thursday, August 21st. LeMaitre Vascular's dividend payout ratio is 38.83%.

Insider Activity at LeMaitre Vascular

In related news, CEO George W. Lemaitre sold 100,000 shares of the stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $93.51, for a total value of $9,351,000.00. Following the completion of the transaction, the chief executive officer owned 1,727,003 shares of the company's stock, valued at approximately $161,492,050.53. This trade represents a 5.47% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director John A. Roush sold 6,561 shares of the stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $92.55, for a total transaction of $607,220.55. Following the completion of the transaction, the director directly owned 2,916 shares of the company's stock, valued at approximately $269,875.80. The trade was a 69.23% decrease in their position. The disclosure for this sale can be found here. Insiders sold 120,815 shares of company stock worth $11,280,206 over the last 90 days. Company insiders own 9.50% of the company's stock.

Institutional Trading of LeMaitre Vascular

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geneva Capital Management LLC increased its position in shares of LeMaitre Vascular by 6.0% during the second quarter. Geneva Capital Management LLC now owns 915,238 shares of the medical instruments supplier's stock worth $76,010,000 after acquiring an additional 51,489 shares during the period. Congress Asset Management Co. increased its holdings in LeMaitre Vascular by 4.6% during the second quarter. Congress Asset Management Co. now owns 673,968 shares of the medical instruments supplier's stock valued at $55,973,000 after buying an additional 29,553 shares during the period. First Trust Advisors LP increased its holdings in LeMaitre Vascular by 52.7% during the second quarter. First Trust Advisors LP now owns 612,028 shares of the medical instruments supplier's stock valued at $50,829,000 after buying an additional 211,280 shares during the period. Geode Capital Management LLC increased its holdings in LeMaitre Vascular by 3.0% during the second quarter. Geode Capital Management LLC now owns 519,792 shares of the medical instruments supplier's stock valued at $43,174,000 after buying an additional 15,036 shares during the period. Finally, Northern Trust Corp increased its holdings in LeMaitre Vascular by 5.4% during the first quarter. Northern Trust Corp now owns 345,563 shares of the medical instruments supplier's stock valued at $28,993,000 after buying an additional 17,748 shares during the period. 84.64% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.